ProQR (PRQR) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ProQR Therapeutics reports a notable increase in revenue for the first nine months of 2024, climbing to €14.6 million from €3.2 million in the previous year, despite incurring higher operating costs. The company’s total assets have decreased from €137.9 million to €106.9 million over the same period, reflecting changes in cash reserves and liabilities. This financial update highlights both growth in revenue and strategic challenges as ProQR navigates its financial landscape.
For further insights into PRQR stock, check out TipRanks’ Stock Analysis page.